
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute Inc. is advancing its clinical-stage biopharmaceutical efforts with promising results from its lead candidate, ersodetug, which has demonstrated substantial improvement in managing hypoglycemia and a favorable safety profile. Notably, discussions with key opinion leaders indicate that approximately 70% of congenital hyperinsulinism patients are unresponsive to standard of care treatments, suggesting a significant market opportunity for Rezolute's efficacious therapies. The company aims to leverage these clinical insights and ongoing research to create value and generate revenue through successful product development and regulatory approvals.
Bears say
The financial outlook for Rezolute Inc appears negative due to its reported 4Q25 net loss of $24.4 million, which aligns closely with consensus estimates of $25.9 million, indicating a lack of profitability. Further compounding the concern, the projected FY25 net loss is anticipated to reach $74.4 million, surpassing earlier consensus estimates of $95 million, reflecting ongoing financial strain. Additionally, potential regulatory delays stemming from FDA staffing issues could hinder the company's progress in obtaining necessary approvals for its drug candidates, adding to uncertainty in its financial future.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares